Skip to main content
PMC home page
Gut logoLink to Gut
. 1993;34(2 Suppl):S91–S94. doi: 10.1136/gut.34.2_suppl.s91

A controlled trial of high dose interferon, alone and after prednisone withdrawal, in the treatment of chronic hepatitis B: long term follow up.

V Perez 1, J Findor 1, H Tanno 1, J Sordá 1
PMCID: PMC1374020  PMID: 8314497

Abstract

This study was designed to evaluate the safety and effectiveness of high dose interferon, with or without prednisone pretreatment, in patients with chronic hepatitis B. Patients were randomised to two treatment groups: group I (n = 26) received six weeks of prednisone followed by a two week, drug free period, and then 10 million units (MU) of interferon alfa-2b three times weekly subcutaneously for 16 weeks; group II (n = 24) were used as controls for 24 weeks and then treated with interferon. Loss of hepatitis B e antigen (HBeAg) and hepatitis B virus (HBV)-DNA, with a return to normal alanine aminotransferase (ALT) activity, was seen in 16 of 26 group I patients (61.5%), in one group II patient (4.2%) during the control phase, and in 13 of 23 group II patients (56.5%) after interferon. Three of 26 (11.5%) in group I and one of 23 (4.3%) in group II eliminated the surface antigen (HBsAg). There were no statistically significant differences in response between groups I and II. Liver biopsies carried out in 20 patients showed that responders had a noticeable reduction in inflammation and disappearance of core antigen in liver tissue, changes not seen in non-responders. On long term follow up (four years), nine out of 28 responders (32.1%) eliminated HBsAg, and four initial non-responders had a late seroconversion.

Full text

PDF
S91

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander G. J., Brahm J., Fagan E. A., Smith H. M., Daniels H. M., Eddleston A. L., Williams R. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. Lancet. 1987 Jul 11;2(8550):66–69. doi: 10.1016/s0140-6736(87)92735-8. [DOI] [PubMed] [Google Scholar]
  2. Brook M. G., Karayiannis P., Thomas H. C. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology. 1989 Nov;10(5):761–763. doi: 10.1002/hep.1840100502. [DOI] [PubMed] [Google Scholar]
  3. Di Bisceglie A. M. Interferon therapy of complicated hepatitis B virus infection. Semin Liver Dis. 1989 Nov;9(4):254–258. doi: 10.1055/s-2008-1040519. [DOI] [PubMed] [Google Scholar]
  4. Hoofnagle J. H. Alpha-interferon therapy of chronic hepatitis B. Current status and recommendations. J Hepatol. 1990;11 (Suppl 1):S100–S107. doi: 10.1016/0168-8278(90)90173-o. [DOI] [PubMed] [Google Scholar]
  5. James O. F. Ursodeoxycholic acid treatment for chronic cholestatic liver disease. J Hepatol. 1990 Jul;11(1):5–8. doi: 10.1016/0168-8278(90)90263-q. [DOI] [PubMed] [Google Scholar]
  6. James O. F. Ursodeoxycholic acid treatment for chronic cholestatic liver disease. J Hepatol. 1990 Jul;11(1):5–8. doi: 10.1016/0168-8278(90)90263-q. [DOI] [PubMed] [Google Scholar]
  7. Korenman J., Baker B., Waggoner J., Everhart J. E., Di Bisceglie A. M., Hoofnagle J. H. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med. 1991 Apr 15;114(8):629–634. doi: 10.7326/0003-4819-114-8-629. [DOI] [PubMed] [Google Scholar]
  8. Lok A. S., Lai C. L., Wu P. C., Lau J. Y., Leung E. K., Wong L. S. Treatment of chronic hepatitis B with interferon: experience in Asian patients. Semin Liver Dis. 1989 Nov;9(4):249–253. doi: 10.1055/s-2008-1040518. [DOI] [PubMed] [Google Scholar]
  9. McDonald J. A., Caruso L., Karayiannis P., Scully L. J., Harris J. R., Forster G. E., Thomas H. C. Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant alpha-interferon. Hepatology. 1987 Jul-Aug;7(4):719–723. doi: 10.1002/hep.1840070417. [DOI] [PubMed] [Google Scholar]
  10. Novick D. M., Lok A. S., Thomas H. C. Diminished responsiveness of homosexual men to antiviral therapy for HBsAg-positive chronic liver disease. J Hepatol. 1985;1(1):29–35. doi: 10.1016/s0168-8278(85)80065-9. [DOI] [PubMed] [Google Scholar]
  11. Omata M., Imazeki F., Yokosuka O., Ito Y., Uchiumi K., Mori J., Okuda K. Recombinant leukocyte a interferon treatment in patients with chronic hepatitis B virus infection. Pharmacokinetics, tolerance, and biologic effects. Gastroenterology. 1985 Apr;88(4):870–880. doi: 10.1016/s0016-5085(85)80002-0. [DOI] [PubMed] [Google Scholar]
  12. Perrillo R. P., Brunt E. M. Hepatic histologic and immunohistochemical changes in chronic hepatitis B after prolonged clearance of hepatitis B e antigen and hepatitis B surface antigen. Ann Intern Med. 1991 Jul 15;115(2):113–115. doi: 10.7326/0003-4819-115-2-113. [DOI] [PubMed] [Google Scholar]
  13. Perrillo R. P., Schiff E. R., Davis G. L., Bodenheimer H. C., Jr, Lindsay K., Payne J., Dienstag J. L., O'Brien C., Tamburro C., Jacobson I. M. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med. 1990 Aug 2;323(5):295–301. doi: 10.1056/NEJM199008023230503. [DOI] [PubMed] [Google Scholar]
  14. Perrillo R. P. Treatment of chronic hepatitis B with interferon: experience in western countries. Semin Liver Dis. 1989 Nov;9(4):240–248. doi: 10.1055/s-2008-1040517. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES